Inimmune’s focus is to discover and develop novel innate immune modulating compounds for treatment of a host of immune diseases. Our team is a world leader in the discovery and development of innate immune stimulants. Currently, the company’s pipeline is focused on utilizing several late-stage Toll-like receptor (TLR) agonists in immuno-oncology, food allergy, and allergic rhinitis. Next generation projects are focused on developing these agents as adjuvants for use with novel phage-based vaccines to prevent Gram-negative bacterial infections and for use with an opioid vaccine to prevent drug overdose.
Inimmune is developing several innate immune modulators for the treatment of various cancers. Our TLR agonists demonstrate synergy with established antibody based therapies. Synergistic therapies may revolutionize the treatment of cancer through improved efficacy and decreased doses, leading to reduced side effects for patients.
Inimmune is investigating the ability of their novel innate immune receptor agonists to modulate the immune system to treat allergic rhinitis. This can be used as a treatment for a specific allergen or used more broadly for seasonal allergies against an unknown allergen.
Inimmune’s primary objective is to develop a next-generation food allergy vaccine to treat patients with both moderate and severe food allergy. There are no currently approved prophylactic treatments for many food allergies. Inimmune’s lead candidate food allergy vaccine is currently in late-stage preclinical studies and will be advancing to clinical toxicity studies in late 2021. The vaccine will be administered sublingually (under the tongue).
Vaccines Against Gram-negative Bacterial Infection & Novel Antibiotics
Our most advanced program focused on prevention of infectious disease is a novel phage-based vaccine to prevent Gram-negative bacterial infections. Having already generated exciting preclinical data, this revolutionary vaccination strategy has widespread implications for preventing multiple high priority pathogens (such as multidrug-resistant Pseudomonas aeruginosa and Acinetobacter) considered to be the greatest threats to human health by the World Health Organization. In a second program, Inimmune is developing a novel class of broad-spectrum antibiotics with excellent activity against methicillin-resistant S. aureus and other gram-positive microbes as well as activity against multiple gram-negative WHO priority pathogens.
Preclinical studies are underway using Inimmune’s toll-like receptor (TLR) agonists in vaccines to treat opioid addiction and prevent COVID-19 infections.
Upper Respiratory Tract Infections
Inimmune is developing immunomodulators to induce broad antiviral innate immunity for the reduction of viral URT and associated exacerbations in asthma and COPD patients.